All Outputs (3)

Evaluating trastuzumab in the treatment of HER2 positive breast cancer (2020)
Journal Article
Jaques, R., Xu, S., & Matsakas, A. (2020). Evaluating trastuzumab in the treatment of HER2 positive breast cancer. Histology and Histopathology, 35(10), 1059-1075. https://doi.org/10.14670/HH-18-221

© 2020, Histology and Histopathology. All rights reserved. The transmembrane oncoprotein HER2 is encoded by ERBB2 gene and overexpressed in around 20% of invasive breast cancers. It can be specifically targeted by Trastuzumab (Herceptin®), a humanise... Read More about Evaluating trastuzumab in the treatment of HER2 positive breast cancer.

Recent advances in drug discovery for diabetic kidney disease (2020)
Journal Article
Danta, C. C., Boa, A. N., Bhandari, S., Sathyapalan, T., & Xu, S. Z. (2021). Recent advances in drug discovery for diabetic kidney disease. Expert Opinion on Drug Discovery, 16(4), 447-461. https://doi.org/10.1080/17460441.2021.1832077

Introduction: Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD), and 40% of patients with diabetes develop DKD. Although some pathophysiological mechanisms and drug targets of DKD have been described, the effectivenes... Read More about Recent advances in drug discovery for diabetic kidney disease.

Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis (2020)
Journal Article
Su, D., Wu, S., & Xu, S. (2020). Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis. Stem Cell Research and Therapy, 11(1), Article 395. https://doi.org/10.1186/s13287-020-01911-4

Background Bone mesenchymal stem cells (MSCs) can promote liver regeneration and inhibit inflammation and hepatic fibrosis. MSCs also can serve as a vehicle for gene therapy. Smad7 is an essential negative regulatory gene in the TGF-β1/Smad signalli... Read More about Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis.